• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺钼靶检查中恶性非毛刺状及非钙化肿块的瘤外征象:它们与乳腺癌的预后因素相关吗?

Extratumoral Signs of Malignant Nonspiculate and Noncalcified Masses on Mammography: Are They Associated With Prognostic Factors in Breast Cancer?

作者信息

Xu Ye, Yang Xinxin, Wang Fei, Wu Dongbo, Sun Jianghong, Meng Hongxue, Zhang Xiushi

机构信息

Department of Radiology, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin 150081, Heilongjiang, China.

Precision Medical Center, Department of Pathology, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin 150081, Heilongjiang, China.

出版信息

Breast J. 2025 Jun 24;2025:2793342. doi: 10.1155/tbj/2793342. eCollection 2025.

DOI:10.1155/tbj/2793342
PMID:40599582
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12213040/
Abstract

To investigate the association between mammographic extratumoral signs, specifically their subclassifications, of nonspiculate and noncalcified masses (NSNCMs) and prognostic factors in breast cancer. This retrospective study analyzed imaging and pathological data from 374 patients, categorizing extratumoral signs into structural abnormalities (parenchymal and trabecular) and halo, while also undergoing subclassification. The focus prognostic factors were achieved through screening. Then, univariate and multivariate analyses were performed. Correlation analysis was also employed to determine the relationship between subclassifications and prognostic factors. Lymphovascular invasion (LVI), Ki-67 levels, and stromal tumor-infiltrating lymphocytes (sTIL) levels were identified as the focus prognostic factors. Among tumor signs, only tumor margin was associated with sTIL levels. Extratumoral trabecular signs exhibited a significant correlation with LVI (OR = 2.5, =0.007) and Ki-67 levels (OR = 1.23, =0.001). Specifically, the parallel sign showed a positive correlation with LVI (=0.009,  = 0.134), while the reticular sign displayed a positive correlation with Ki-67 levels (=0.009,  = 0.134). Extratumoral parenchymal signs were found to be an independent predictor for sTIL levels (OR = 0.64, < 0.001), with a negative correlation observed between the contraction sign and sTIL levels ( < 0.001,  = -0.185), as well as between the atrophy sign and sTIL levels (=0.046,  = -0.103). Specific extratumoral structural abnormalities of mammographic malignant NSNCMs showed a significant correlation with prognostic factors in breast cancer, warranting increased attention in research and clinical practice.

摘要

研究乳腺钼靶检查中肿瘤外体征,特别是其亚分类,与非毛刺状和非钙化肿块(NSNCMs)的乳腺癌预后因素之间的关联。这项回顾性研究分析了374例患者的影像和病理数据,将肿瘤外体征分为结构异常(实质和小梁)和晕征,并进行了亚分类。通过筛查确定重点预后因素。然后进行单因素和多因素分析。还采用相关分析来确定亚分类与预后因素之间的关系。确定血管淋巴管浸润(LVI)、Ki-67水平和基质肿瘤浸润淋巴细胞(sTIL)水平为重点预后因素。在肿瘤体征中,只有肿瘤边缘与sTIL水平相关。肿瘤外小梁征与LVI(OR = 2.5,P = 0.007)和Ki-67水平(OR = 1.23,P = 0.001)呈显著相关。具体而言,平行征与LVI呈正相关(P = 0.009,r = 0.134),而网状征与Ki-67水平呈正相关(P = 0.009,r = 0.134)。发现肿瘤外实质征是sTIL水平的独立预测因素(OR = 0.64,P < 0.001),收缩征与sTIL水平之间呈负相关(P < 0.001,r = -0.185),萎缩征与sTIL水平之间也呈负相关(P = 0.046,r = -0.103)。乳腺钼靶恶性NSNCMs的特定肿瘤外结构异常与乳腺癌预后因素呈显著相关,值得在研究和临床实践中给予更多关注。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/958a/12213040/142d6b55d298/TBJ2025-2793342.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/958a/12213040/8470aab0fb1b/TBJ2025-2793342.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/958a/12213040/122d2a9b0236/TBJ2025-2793342.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/958a/12213040/4e01e28ebed1/TBJ2025-2793342.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/958a/12213040/c0acb97f2275/TBJ2025-2793342.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/958a/12213040/461e64471739/TBJ2025-2793342.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/958a/12213040/142d6b55d298/TBJ2025-2793342.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/958a/12213040/8470aab0fb1b/TBJ2025-2793342.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/958a/12213040/122d2a9b0236/TBJ2025-2793342.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/958a/12213040/4e01e28ebed1/TBJ2025-2793342.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/958a/12213040/c0acb97f2275/TBJ2025-2793342.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/958a/12213040/461e64471739/TBJ2025-2793342.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/958a/12213040/142d6b55d298/TBJ2025-2793342.006.jpg

相似文献

1
Extratumoral Signs of Malignant Nonspiculate and Noncalcified Masses on Mammography: Are They Associated With Prognostic Factors in Breast Cancer?乳腺钼靶检查中恶性非毛刺状及非钙化肿块的瘤外征象:它们与乳腺癌的预后因素相关吗?
Breast J. 2025 Jun 24;2025:2793342. doi: 10.1155/tbj/2793342. eCollection 2025.
2
Focus on the Predictive Value of Subclassification of Extratumoral Structural Abnormalities for Malignant Nonspiculate and Noncalcified Masses on Digital Mammography.关注数字化乳腺摄影中肿瘤外结构异常亚分类对恶性非毛刺状和非钙化肿块的预测价值。
Front Genet. 2022 Feb 4;13:822858. doi: 10.3389/fgene.2022.822858. eCollection 2022.
3
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
4
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?当前的生存预测工具在治疗骨转移后的骨骼相关事件时有用吗?
Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22.
5
Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy.未经化疗治疗的 I 期三阴性乳腺癌患者的肿瘤浸润淋巴细胞。
JAMA Oncol. 2024 Aug 1;10(8):1077-1086. doi: 10.1001/jamaoncol.2024.1917.
6
Prognostic factors for return to work in breast cancer survivors.乳腺癌幸存者恢复工作的预后因素。
Cochrane Database Syst Rev. 2025 May 7;5(5):CD015124. doi: 10.1002/14651858.CD015124.pub2.
7
Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review.乳腺密度、内分泌治疗与乳腺癌风险:预后和预测生物标志物综述。
Cochrane Database Syst Rev. 2021 Oct 26;10(10):CD013091. doi: 10.1002/14651858.CD013091.pub2.
8
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
9
Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk.乳腺 X 线摄影联合乳腺超声与乳腺 X 线摄影用于一般风险女性乳腺癌筛查。
Cochrane Database Syst Rev. 2023 Mar 31;3(3):CD009632. doi: 10.1002/14651858.CD009632.pub3.
10
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.

本文引用的文献

1
A real-world clinicopathological model for predicting pathological complete response to neoadjuvant chemotherapy in breast cancer.一种用于预测乳腺癌新辅助化疗病理完全缓解的真实世界临床病理模型。
Front Oncol. 2024 Feb 14;14:1323226. doi: 10.3389/fonc.2024.1323226. eCollection 2024.
2
Prognostic value and distribution pattern of tumor infiltrating lymphocytes and their subsets in distant metastases of advanced breast cancer.晚期乳腺癌远处转移中肿瘤浸润淋巴细胞及其亚群的预后价值及分布模式。
Clin Breast Cancer. 2024 Apr;24(3):e167-e176. doi: 10.1016/j.clbc.2023.12.011. Epub 2023 Dec 30.
3
Optimal treatment strategy for hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer patients with 1-2 suspicious axillary lymph node metastases on breast magnetic resonance imaging: upfront surgery vs. neoadjuvant chemotherapy.
乳腺磁共振成像显示有1-2个可疑腋窝淋巴结转移的激素受体阳性、人表皮生长因子受体2阴性乳腺癌患者的最佳治疗策略: upfront手术与新辅助化疗对比
Front Oncol. 2023 May 17;13:936148. doi: 10.3389/fonc.2023.936148. eCollection 2023.
4
The ratio of intratumour to stromal infiltrating lymphocytes better predicts prognosis in breast cancer.肿瘤内浸润淋巴细胞与基质浸润淋巴细胞的比例能更好地预测乳腺癌的预后。
Clin Transl Med. 2023 May;13(5):e1265. doi: 10.1002/ctm2.1265.
5
Tumor-associated fibrosis impairs the response to immunotherapy.肿瘤相关纤维化会影响免疫治疗的效果。
Matrix Biol. 2023 May;119:125-140. doi: 10.1016/j.matbio.2023.04.002. Epub 2023 Apr 18.
6
Focus on the Predictive Value of Subclassification of Extratumoral Structural Abnormalities for Malignant Nonspiculate and Noncalcified Masses on Digital Mammography.关注数字化乳腺摄影中肿瘤外结构异常亚分类对恶性非毛刺状和非钙化肿块的预测价值。
Front Genet. 2022 Feb 4;13:822858. doi: 10.3389/fgene.2022.822858. eCollection 2022.
7
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
8
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.乳腺癌中肿瘤浸润淋巴细胞的故事:国际免疫肿瘤生物标志物工作组的报告
NPJ Breast Cancer. 2021 Dec 1;7(1):150. doi: 10.1038/s41523-021-00346-1.
9
Tumor Microenvironment in Breast Cancer-Updates on Therapeutic Implications and Pathologic Assessment.乳腺癌中的肿瘤微环境——治疗意义与病理评估的最新进展
Cancers (Basel). 2021 Aug 23;13(16):4233. doi: 10.3390/cancers13164233.
10
An Evaluation of Clinicopathological Correlation and Outcome of Human Epidermal Growth Factor Receptor 2 Subgroups Reclassified According to the Latest ASCO/CAP Guideline.根据最新的 ASCO/CAP 指南对人表皮生长因子受体 2 亚组进行重新分类的临床病理相关性和结果评估。
Clin Breast Cancer. 2022 Jan;22(1):e114-e122. doi: 10.1016/j.clbc.2021.05.005. Epub 2021 May 17.